CSL: From the 1916 Government Serum Labo

Multi-region · Healthcare / Elderly Care · Founder Journeys

CSL: From the 1916 Government Serum Labo Multi-region · Healthcare / Elderly Care · Founder Journeys 01 / 发家路径 02 / 失败与拐点 03 / 关键数据 起步 探索 增长 Foundati… · 1916 · 发家路径 › 起步 Foundati… 1916 Privatiz… · 1994 · 发家路径 › 探索 Privatiz… 1994 Plasma G… · 2002 · 发家路径 › 增长 Plasma G… 2002 核心数据 · 2026 Reven… · 关键数据 › 起步 核心数据 2026 Reven… Legend User UI Agent logic Policy Tool action Context / trace

失败与踩坑

  • • Prior to the 1990s
  • • A global plasma oversupply in the early …
  • • Post-acquisition integration of Vifor af…
  • • Failure in the development of the CSL112…
  • • Management turbulence in 2026 saw CEO Pa…

关键成功要素

  • • In 1916
  • • Following corporatization in 1991
  • • Plasma products represent an exceptional…
  • • Long-term focus on long-cycle product li…
  • • Plasma utilization and lowest-cost opera…

经验教训

  • • Once a national laboratory completes ins…
  • • External trade and regulatory pressures …
  • • In the oligopolistic plasma products ind…
  • • Integration and impairment risks followi…
  • • The return of industry veterans and deci…

Workflow diagram • Built with Archify • Create yours ↗ • Hover to trace • R route • Click to focus • +/− zoom • M radar • T theme • E export